

Alessandra Minelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6923807/publications.pdf>

Version: 2024-02-01

62
papers

1,794
citations

361413

20
h-index

302126

39
g-index

65
all docs

65
docs citations

65
times ranked

4106
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association studies on Northern Italy isolated populations provide further support concerning genetic susceptibility for major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 135-148.	2.6	1
2	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	2.6	4
3	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.7	19
4	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 55, 112-157.	0.7	7
5	The Elephant in the Room: A Cross-Sectional Study on the Stressful Psychological Effects of the COVID-19 Pandemic in Mental Healthcare Workers. <i>Brain Sciences</i> , 2022, 12, 408.	2.3	23
6	Genetic Dissection of Temperament Personality Traits in Italian Isolates. <i>Genes</i> , 2022, 13, 4.	2.4	2
7	Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review. <i>European Neuropsychopharmacology</i> , 2022, 59, 68-81.	0.7	5
8	Biological correlates of early life stressful events in major depressive disorder. <i>Psychoneuroendocrinology</i> , 2021, 125, 105103.	2.7	23
9	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. <i>Pharmacogenomics Journal</i> , 2021, 21, 85-93.	2.0	1
10	Alterations observed in the interferon β and γ signaling pathway in MDD patients are marginally influenced by cis-acting alleles. <i>Scientific Reports</i> , 2021, 11, 727.	3.3	1
11	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. <i>Stem Cell Research</i> , 2021, 51, 102216.	0.7	2
12	Evidence of an interaction between <i>FXR1</i> and <i>GSK3β</i> polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. <i>European Psychiatry</i> , 2021, 64, e39.	0.2	6
13	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. <i>Brain Sciences</i> , 2021, 11, 1120.	2.3	11
14	Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1100.	2.5	3
15	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. <i>H\ddot{u}rtige Utbildning</i> , 2021, 12, 1987655.	3.0	16
16	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) <i>Tj ETQq0 0 0 rgBI.4 Overlock 10 Tf 50</i>		
17	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 921-932.	3.2	22
18	Childhood trauma and glucose metabolism in patients with first-episode psychosis. <i>Psychoneuroendocrinology</i> , 2020, 113, 104536.	2.7	15

#	ARTICLE	IF	CITATIONS
19	Social Cognition in a Research Domain Criteria Perspective: A Bridge Between Schizophrenia and Autism Spectra Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 806.	2.6	27
20	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. <i>Genes</i> , 2020, 11, 1089.	2.4	17
21	Assessment of haptoglobin alleles in autism spectrum disorders. <i>Scientific Reports</i> , 2020, 10, 7758.	3.3	2
22	Association study between <i>HTR2A</i> rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. <i>Drug Development Research</i> , 2020, 81, 754-761.	2.9	15
23	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. <i>Drug Development Research</i> , 2020, 81, 593-599.	2.9	14
24	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. <i>Stem Cell Research</i> , 2020, 49, 102104.	0.7	1
25	F49GENETIC DETERMINANTS OF CIRCULATING VEGF LEVELS IN MAJOR DEPRESSIVE DISORDER. <i>European Neuropsychopharmacology</i> , 2019, 29, S1135-S1136.	0.7	0
26	Clinical efficacy of trauma-focused psychotherapies in treatment-resistant depression (TRD) in-patients: A randomized, controlled pilot-study. <i>Psychiatry Research</i> , 2019, 273, 567-574.	3.3	23
27	Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. <i>Frontiers in Pharmacology</i> , 2019, 10, 402.	3.5	35
28	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. <i>Journal of ECT</i> , 2019, 35, 189-194.	0.6	19
29	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 610-618.	2.6	12
30	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2307-2312.	2.2	7
31	The effect of childhood trauma on blood transcriptome expression in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 104, 50-54.	3.1	14
32	The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. <i>Pharmacogenomics Journal</i> , 2017, 17, 146-154.	2.0	37
33	Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. <i>Journal of Affective Disorders</i> , 2017, 208, 443-447.	4.1	15
34	Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways. <i>PLoS ONE</i> , 2017, 12, e0182778.	2.5	14
35	Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response. <i>Journal of ECT</i> , 2016, 32, 88-92.	0.6	47
36	Electroconvulsive Therapy in a Patient With Chronic Catatonia. <i>Journal of ECT</i> , 2016, 32, 222-223.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Influence of GRIK4 genetic variants on the electroconvulsive therapy response. <i>Neuroscience Letters</i> , 2016, 626, 94-98.	2.1	10
38	Meta-analysis of Genome-Wide Association Studies for Extraversion: Findings from the Genetics of Personality Consortium. <i>Behavior Genetics</i> , 2016, 46, 170-182.	2.1	178
39	The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia. <i>Current Neuropharmacology</i> , 2016, 14, 540-550.	2.9	16
40	The role of <i>GRIK4</i> gene in treatment-resistant depression. <i>Genetical Research</i> , 2015, 97, e14.	0.9	19
41	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. <i>PLoS ONE</i> , 2015, 10, e0116686.	2.5	65
42	Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2015, 72, 642.	11.0	289
43	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 183, 179-186.	4.1	17
44	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. <i>Translational Psychiatry</i> , 2015, 5, e687-e687.	4.8	26
45	The role of the potassium channel gene <i>KCNK2</i> in major depressive disorder. <i>Psychiatry Research</i> , 2015, 225, 489-492.	3.3	10
46	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 461-466.	4.5	34
47	Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of <i>DAO</i> , <i>DAOA</i> , <i>PPP3CC</i> , and <i>DTNBP1</i> genes. <i>BMC Medical Genetics</i> , 2013, 14, 33.	2.1	26
48	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. <i>Depression and Anxiety</i> , 2013, 30, 1170-1176.	4.1	42
49	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. <i>BMC Psychiatry</i> , 2012, 12, 145.	2.6	16
50	Effectiveness of cognitive behavioral therapy in the treatment of fibromyalgia syndrome: a meta-analytic literature review. <i>Reumatismo</i> , 2012, 64, 151-7.	0.9	9
51	<i>PCLO</i> gene: Its role in vulnerability to major depressive disorder. <i>Journal of Affective Disorders</i> , 2012, 139, 250-255.	4.1	20
52	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1322-1325.	4.8	73
53	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 323-329.	3.2	54
54	The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. <i>BMC Psychiatry</i> , 2011, 11, 50.	2.6	39

#	ARTICLE	IF	CITATIONS
55	Effects of intravenous antidepressant drugs on the excitability of human motor cortex: a study with paired magnetic stimulation on depressed patients. <i>Brain Stimulation</i> , 2010, 3, 15-21.	1.6	27
56	New Copy Number Variations in Schizophrenia. <i>PLoS ONE</i> , 2010, 5, e13422.	2.5	82
57	Serotonin transporter gene polymorphisms and treatment-resistant depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 934-939.	4.8	38
58	On the neural control of social emotional behavior. <i>Social Cognitive and Affective Neuroscience</i> , 2009, 4, 50-58.	3.0	132
59	An Association of GRIK3 Ser310Ala Functional Polymorphism with Personality Traits. <i>Neuropsychobiology</i> , 2009, 59, 28-33.	1.9	16
60	Personality Traits in an Italian Sample: Relationship with Anxiety and Depression. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2009, 5, 26-30.	1.2	16
61	Long-lasting effects of high frequency repetitive transcranial magnetic stimulation in major depressed patients. <i>Psychiatry Research</i> , 2007, 150, 181-186.	3.3	63
62	Lateralized readiness potential elicited by undetected visual stimuli. <i>Experimental Brain Research</i> , 2007, 179, 683-690.	1.5	12